BioSpace News Archive

Biocept, Inc announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announces that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® (INN melphalan flufenamide, also called melflufen) in the US.

Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for somatrogon.

Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), today jointly announced with Eli Lilly and Company (“Lilly”, NYSE: LLY) the final clinical outcome and biomarker analysis of the open label, phase Ib study (NCT04072679) of sintilimab plus bevacizumab biosimilar injection for advanced hepatocellular carcinoma.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 2, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 first quarter ended December 31, 2021.

Core One Labs Inc. is pleased to announce that its wholly owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has optimized its recombinant production system (the “System”).

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that on January 21, 2022, the Company approved the grant of inducement stock options covering an aggregate of 117,000 shares of Iovance’s common stock to thirteen new non-executive employees.

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.

Ocugen, Inc. announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 787,268 shares of its common stock and restricted stock units covering an aggregate of 217,681 shares of common stock to three newly hired team members.

Today, the U.S. Food and Drug Administration took two actions to expand the use of the antiviral drug Veklury (remdesivir) to certain non-hospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease.